Marstacimab Alternatives Compared
| Marstacimab | Advate (antihemophilic factor) | Recombinate (antihemophilic factor) |
|
|---|
| Marstacimab | Advate (antihemophilic factor) | Recombinate (antihemophilic factor) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemophilia A, Hemophilia B. Marstacimab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A. Advate may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A. Recombinate may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||
| More about Marstacimab | More about Advate (antihemophilic factor) | More about Recombinate (antihemophilic factor) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Advate has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Recombinate has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Marstacimab side effects |
View all Advate side effects |
View all Recombinate side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Advate prices |
View all Recombinate prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Hympavzi | Other antihemophilic factor brands include: Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Recombinate, Xyntha View more | Other antihemophilic factor brands include: Advate, Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Xyntha View more | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
720 hours |
24 hours |
24 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 9 drugs are known to interact with Marstacimab:
|
A total of 8 drugs are known to interact with Advate:
|
A total of 8 drugs are known to interact with Recombinate:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.